Bradford Siegele, MD, JD
Anatomic and Clinical
Locations
Practice Locations
UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
720-848-0000
Children's Hospital Colorado Anschutz Medical Campus
Aurora
720-777-1234
Provider Expertise
Specialties
- Pediatric Pathology ( 2017 )
- Anatomic and Clinical ( 2016 )
- Hematology ( 2018 )
Conditions & Treatments
-
Cancers
Aplastic Anemia, Cancer Pathology, Leukemia (Adult Acute), Leukemia (Adult Chronic), Leukemia (Childhood), Lymphoma, Myelodysplastic Syndrome, Myeloma, Pediatric Cancer, Sarcoma
-
Child and Teen Health
Pediatric Diseases and Conditions, Teen Health
-
Blood / Lymphatic System
Education & Training
Medical Schools
MD, University of Texas Southwestern Medical Center at Dallas Southwestern Medical School (2012)
Undergraduate Schools
BA, Duke University (NC) (1999)
Graduate Schools
JD, Harvard University (2005)
Residency Program
University of Colorado (University Hospital) Program (2016)
Fellowships
Massachusetts General Hospital Program (2018)
Dana-Farber Cancer Institute/Boston Children’s Hospital/Harvard Medical School Program (2017)
Professional Memberships
American Society for Clinical Pathology, Member
College of American Pathologists, Member
Society for Pediatric Pathology, Member
Research & Grants
Grants
Vickery-Colvin Research Grant ("Immunohistochemical and Molecular Methods for Detection of DUX4 Translocations in B-Lymphoblastic Leukemia/Lymphoma") (2018)
Research Interests for Patients
My research interests are primarily focused on characterizing and investigating tools for diagnosis of pediatric, adolescent/young adult, and adult leukemias and lymphomas.
information for referring providers
Referral Contact Phone
720-848-0000
Research Interest for Referring Providers
My research interests are primarily focused on characterizing and investigating tools for diagnosis of pediatric, adolescent/young adult, and adult leukemias and lymphomas, with a special emphasis on emerging diseases including DUX4-IgG translocated ALL, Ph-like ALL, pediatric MDS, and myeloid neoplasms with germline predisposition.
